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36 The effect of ivacaftor therapy on clinical and PCR-identiﬁed
microbial diversity of cystic ﬁbrosis lung infection
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A. Horsley1,2, E. Mahenthiralingam3. 1University Hospital of South Manchester
NHS Foundation Trust, Manchester Adult Cystic Fibrosis Centre, Manchester,
United Kingdom; 2University of Manchester, Institute of Inﬂammation and Repair,
Manchester, United Kingdom; 3Cardiff University, Cardiff School of Biosciences,
Cardiff, United Kingdom
Objectives: Ivacaftor is licensed for CF patients with the G551D mutation. Clinical
beneﬁts of ivacaftor have been demonstrated, but its impact on microbial diversity
of chronic lung infection has not. The aim of this study was to investigate whether
expected rapid improvement in FEV1 from restoring CFTR function using ivacaftor
is associated with early changes in airway microbiology.
Methods: Paired sputum samples were obtained from 13 of 14 recruited adult
CF patients immediately prior to ivacaftor therapy, and after 1 and/or 3 months of
treatment. Samples underwent routine microbiology, and extraction of total nucleic
acids using a standardised automated method. Ribosomal Intergenic Spacer Analysis
(RISA) qualitatively investigated sputum bacterial diversity and 16s rRNA gene
pyrosequencing used for detailed analysis. FEV1 was measured at each visit, and
sweat chloride (a marker of CFTR function) was assessed pre-treatment and at
2 months.
Results: 10 of 14 subjects had samples at all three timepoints. Mean FEV1 percent
predicted improved from 56 to 63% at 1 month (p< 0.01). Mean sweat chloride
improved from 115 to 54mmol/L (p< 0.01). Culture, RISA and pyrosequencing
analysis demonstrated no major changes in microbial diversity, especially with
regards to the dominant pathogen, pre- and post-treatment. However, 10 patients
had a reduction in the number pyrosequencing reads attributable to Streptococcus
for the 3 month samples (p< 0.05).
Conclusion: Airway microbiology was largely unaltered in the 3 months after
starting ivacaftor. These ﬁndings suggest that the improvement of FEV1 seen is
not due to changes in airway pathogens.
37 Clinical outcomes of real world Kalydeco (CORK) study
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Objectives: Ivacaftor (KalydecoTM) produces signiﬁcant beneﬁt in patients with
cystic ﬁbrosis with the G551D mutation. Cork University Hospital (CUH) has the
highest worldwide prevalence for this mutation at 21% making it uniquely placed
to provide single centre insight into real world response to treatment.
Methods: With Irish reimbursement of ivacaftor resolved in March 2013, 29
ivacaftor-naive patients with cystic ﬁbrosis (age 6) consented and completed
6 months prospective routine clinical quarterly follow up where change pre and
post ivacaftor were recorded.
Results: At 3 months a signiﬁcant absolute improvement in mean FEV1 percent
predicted of 10.35% (P< 0.001), 2.73 kg mean increase in weight (P< 0.001),
0.83 kg/m2 increase in BMI (P< 0.001), 57.97mmol/l mean reduction in sweat
chloride (P< 0.001) and a 147.4 metre increase in walk test (P = 0.001) were
observed. Beneﬁts were maintained at 6 months. CFQ-R increased for respiratory
(mean 16.55, P = 0.005), weight (mean 31.1, P = 0.019), and body image (mean
17.79, P = 0.009) domains at 3 months. Improvements were signiﬁcantly maintained
at 6 months. Care givers completed care-giver CFQ-R for patients younger than
14 years with similar results. There was a signiﬁcant reduction in the likelihood
of requiring intravenous antibiotics (Relative Risk = 0.069, CI 0.001 to 0.49) in
the 6 months post-Ivacaftor compared to the corresponding 6 month period pre-
Ivacaftor.
Conclusion: In a large single centre cohort with the G551D mutation we report real
world sustained efﬁcacy, tolerability and satisfaction with ivacaftor at 6 months.
38 Cayston® in clinical practice − experiences from a UK adult
CF unit
E.A. Lloyd1, R. Sapina-Vivo1, M. Jackson1, E. Spencer-Clegg1, M. Walshaw1,
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Objectives: Aztreonam lysine (Cayston®) was funded by NHS England as a third-
line inhalation antibiotic in February 2013, and since then we have used it in selected
adult CF patients who fulﬁl the prescription protocol. We report our experience with
this expensive drug to date.
Method: We reviewed clinical parameters including lung function, other inhaled
antibiotics used, use of IV antibiotics, adherence to treatment (from pharmacy
dispensing records), and patient reported outcomes (PROM).
Results: Following a test dose, 24 patients (mean FEV1 34.7% predicted [range
17−77], 8.4% of our clinic) commenced Cayston®. However, 3 developed subse-
quent chest tightness and stopped the medication (at 3−21 days), and a further 3
have died. 14 alternate with inhaled tobramycin, 3 with colomycin, and 2 use it
alone. For 8 patients with more than 6 months data, 6 have improved spirometry and
7 a reduction in the requirement for IV therapy. Pharmacy dispensing records show
high adherence to collection. 19/24 completed a PROM. Whilst only 1 reported
a signiﬁcant decrease in sputum or breathlessness, all report feeling better in the
Cayston® month. Only minimal side effects are reported from the 19 who continue
to use, mainly cough. All 8 in the >6 month group report an improved quality of
life reﬂected in increased or stabilised FEV1 and reduction in IV days.
Conclusions: Cayston® seems to be a well-tolerated medication which has im-
proved the clinical state of a selected group of our adult CF patients and improved
their quality of life. We will continue to monitor the use of this expensive therapy
in our clinic.
39 ‘Real world’ tolerability, ease of use, patient satisfaction and
reported adherence in CF adults commencing Colobreathe®
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Objectives: Colobreathe® dry powder inhaler (CSDPI) is a new inhaled formu-
lation of colistimethate sodium, recently introduced for CF patients infected with
P. aeruginosa. We conducted this study to assess our initial clinical experience with
CSDPI at a large regional UK adult CF centre.
Methods: Demographics and reason for switching to CSDPI were recorded at test
dose. Spirometry and side effects were recorded at test dose and 1-month review.
Patients rated: ease of use, time taken, satisfaction, effectiveness and estimated
adherence to nebulised colistimethate sodium (NCS) compared with CSDPI, as
well as their likelihood to continue with CSDPI and their treatment preference.
Results: 13 patients (6 male) with median age 33 yrs, FEV1 63% predicted were
recruited. 8 patients trialled CSDPI due to intolerance of NCS (INTOL group) and
5 patients due to poor adherence to NCS (ADH group). At 1-month review, 6/8
patients in the INTOL group successfully tolerated CSDPI and planned to continue.
In the ADH group, reported adherence at 1-month review was higher with CSDPI
(median 100% of doses) compared with NCS (50% of doses, p = 0.02). Combining
both groups, FEV1 did not change from baseline to 1-month visits (p = 0.4). CSDPI
was reported to be easier to use than NCS, less time consuming and all patients,
despite some initial reports of device functioning issues, expressed a preference for
CSDPI.
Conclusion: Early ‘real world’ evidence suggests that CSDPI is well tolerated,
easier to use, less inconvenient and associated with improved adherence. Longer-
term outcomes are needed to assess whether these beneﬁts are maintained and are
associated with improved clinical outcomes.
